Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
(PresseBox) (Hamburg, ) — Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE marked deep learning algorithm for Lung Cancer diagnosis. “Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI“ is a plug-and-play AI solution to detect and quantify PD-L1 expression within user-defined Regions of Interest (RoI) in non-small-cell lung carcinoma (NSCLC). In a study (publication pending) the innovative and easy to use software showed a 96.5% agreement for the most relevant scanners on the market and helps experts to get reproducible and accurate results.
“Our Lung PD-L1 is a milestone in supporting pathologists in the diagnosis of Lung Cancer, which is among the most difficult tasks for pathologists. It identifies tumorous cells and quantifies them to support TPS-scoring“, says Mindpeak’s CEO and founder Felix Faber. Mindpeak Lung PD-L1 RoI is available in the EU as a CE-IVD marked medical device. Outside the EU, Mindpeak Lung PD-L1 RoI is Research Use Only, not for use in diagnostic procedures. Lung PD-L1 RoI is part of a new product series of Mindpeak and is the 7th CE marked product of the Hamburg based company.
Founded by Faber and Dr. Lang, the company has been developing AI- software for pathologists since 2018. In doing so, Mindpeak has developed the first AI solution for digital pathology to make it into clinical routine in both Europe and the US. In partnership with international laboratories and leading pathology system providers, Mindpeak continues to expand its product range and develop it into an indispensable part of the digitized pathology workflow. This has made Mindpeak the most integrated company in this field globally.
SOURCE: PresseBox
